Vaxart (VXRT) Says New Data from Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses

Go back to Vaxart (VXRT) Says New Data from Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses
(NASDAQ: VXRT) Delayed: 0.32 --0 (-0%)
Previous Close $0.32    52 Week High $ 
Open $0.32    52 Week Low $ 
Day High $0.32    P/E N/A 
Day Low $0.32    EPS $ 
Volume 140,134